Objective

---

To create a comprehensive landscape of assets for a given disease indication and conduct an in-depth comparative assessment based on multiple parameters to prioritize value-creating opportunities for in-licensing/M&A leveraging our AI based platform, RxAgentAI.

Methodology

---

1. Landscape Generation: Comprehensive screening of opportunities and data gathering:

• Our AI platform, combined with expert insights, creates a comprehensive landscape of opportunities based on client-provided inputs related to the indication(s) of interest and candidate compounds.
• The landscape is constructed and classified based on various parameters related to the candidate compounds such as:
• Indications, Targets/MoA, Phase of Development, Route of Administration (RoA), Modality etc.
• Trial data for in-development candidate compounds and SoC (current & future): study type, sample size, trial duration, trial feasibility, inclusion/exclusion criteria, endpoints and clinical outcomes.

2. Comparative Assessment:

• Automated comparative assessment of assets using a robust 3-dimensional framework is conducted.
• The platform driven analysis and outcome is validated by a team of cross-functional experts to ensure accuracy and relevance.
• Dashboard of prioritized opportunities is shared with the client

3. Detailed Analysis and Report Generation: Asset Profile

• In consultation with client, a comprehensive business case on selected actionable candidate compounds will be generated
• The final insights and recommendations are shared with the client, with all the background information and supporting evidence that aids in making informed decision about the candidate compounds for in-licensing/M&A.

4. Monitoring of the Assets:

• Continuous data gathering and real-time monitoring of candidate compounds, with automatic performance assessments and alerts for significant changes.
• Ongoing re-ranking of assets based on updated insights, ensuring focus on high-potential opportunities, supported by regular reports with actionable recommendations.

Outcomes / Impact

---

• Strategic Decision-Making: Facilitates the identification of value creating compounds with the potential to address unmet medical needs and offering differentiation over existing assets and SoC.
• Portfolio Optimization: Significant value addition to the client's current portfolio by identifying high-potential assets that aligns with their strategic goals.
• Real-time Insights: Enhanced decision-making agility through real-time data, enabling timely identification and prioritization of high potential assets.